Last reviewed · How we verify
HUACHANSU PIAN
Huachansu is a traditional Chinese medicine extract derived from toad secretions that contains bufadienolides and other bioactive compounds with potential anti-tumor and immunomodulatory properties.
Huachansu is a traditional Chinese medicine extract derived from toad secretions that contains bufadienolides and other bioactive compounds with potential anti-tumor and immunomodulatory properties. Used for Cancer (various types, traditional indication), Cardiac arrhythmias (traditional use).
At a glance
| Generic name | HUACHANSU PIAN |
|---|---|
| Also known as | HUACHANSU PIAN（999） |
| Sponsor | Beijing Shenogen Biomedical Co., Ltd |
| Drug class | Traditional Chinese medicine extract; natural product |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Huachansu contains cardiac glycosides and bufadienolides that may inhibit Na+/K+-ATPase and induce apoptosis in cancer cells. The extract also exhibits immunomodulatory effects that may enhance natural killer cell activity and promote anti-tumor immune responses. Traditional use suggests cardiotonic and anti-arrhythmic properties alongside potential cytotoxic activity against malignant cells.
Approved indications
- Cancer (various types, traditional indication)
- Cardiac arrhythmias (traditional use)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Cardiac toxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HUACHANSU PIAN CI brief — competitive landscape report
- HUACHANSU PIAN updates RSS · CI watch RSS
- Beijing Shenogen Biomedical Co., Ltd portfolio CI